
QGEN Valuation
Qiagen NV
- Overview
- Forecast
- Valuation
- Earnings
QGEN Relative Valuation
QGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, QGEN is overvalued; if below, it's undervalued.
Historical Valuation
Qiagen NV (QGEN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 19.02 is considered Undervalued compared with the five-year average of 21.52. The fair price of Qiagen NV (QGEN) is between 54.97 to 64.15 according to relative valuation methord. Compared to the current price of 45.87 USD , Qiagen NV is Undervalued By 16.57%.
Relative Value
Fair Zone
54.97-64.15
Current Price:45.87
16.57%
Undervalued
19.02
PE
1Y
3Y
5Y
Trailing
Forward
13.18
EV/EBITDA
Qiagen NV. (QGEN) has a current EV/EBITDA of 13.18. The 5-year average EV/EBITDA is 14.80. The thresholds are as follows: Strongly Undervalued below 11.83, Undervalued between 11.83 and 13.31, Fairly Valued between 16.28 and 13.31, Overvalued between 16.28 and 17.76, and Strongly Overvalued above 17.76. The current Forward EV/EBITDA of 13.18 falls within the Undervalued range.
16.41
EV/EBIT
Qiagen NV. (QGEN) has a current EV/EBIT of 16.41. The 5-year average EV/EBIT is 18.73. The thresholds are as follows: Strongly Undervalued below 14.95, Undervalued between 14.95 and 16.84, Fairly Valued between 20.62 and 16.84, Overvalued between 20.62 and 22.51, and Strongly Overvalued above 22.51. The current Forward EV/EBIT of 16.41 falls within the Undervalued range.
4.68
PS
Qiagen NV. (QGEN) has a current PS of 4.68. The 5-year average PS is 5.14. The thresholds are as follows: Strongly Undervalued below 4.13, Undervalued between 4.13 and 4.64, Fairly Valued between 5.65 and 4.64, Overvalued between 5.65 and 6.15, and Strongly Overvalued above 6.15. The current Forward PS of 4.68 falls within the Historic Trend Line -Fairly Valued range.
14.52
P/OCF
Qiagen NV. (QGEN) has a current P/OCF of 14.52. The 5-year average P/OCF is 16.49. The thresholds are as follows: Strongly Undervalued below 12.90, Undervalued between 12.90 and 14.69, Fairly Valued between 18.29 and 14.69, Overvalued between 18.29 and 20.08, and Strongly Overvalued above 20.08. The current Forward P/OCF of 14.52 falls within the Undervalued range.
21.11
P/FCF
Qiagen NV. (QGEN) has a current P/FCF of 21.11. The 5-year average P/FCF is 22.38. The thresholds are as follows: Strongly Undervalued below 14.69, Undervalued between 14.69 and 18.53, Fairly Valued between 26.22 and 18.53, Overvalued between 26.22 and 30.07, and Strongly Overvalued above 30.07. The current Forward P/FCF of 21.11 falls within the Historic Trend Line -Fairly Valued range.
Qiagen NV (QGEN) has a current Price-to-Book (P/B) ratio of 2.83. Compared to its 3-year average P/B ratio of 2.80 , the current P/B ratio is approximately 0.90% higher. Relative to its 5-year average P/B ratio of 3.26, the current P/B ratio is about -13.27% higher. Qiagen NV (QGEN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 4.72%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 4.46% , the current FCF yield is about -100.00% lower.
2.83
P/B
Median3y
2.80
Median5y
3.26
5.00
FCF Yield
Median3y
4.72
Median5y
4.46
Competitors Valuation Multiple
The average P/S ratio for QGEN's competitors is , providing a benchmark for relative valuation. Qiagen NV Corp (QGEN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 7.49%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of QGEN increased by 2.04% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 11.10 to 27.01.
The secondary factor is the Revenue Growth, contributed 7.49%to the performance.
Overall, the performance of QGEN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

PSN
Parsons Corp
82.885
USD
+1.91%

OHI
Omega Healthcare Investors Inc
41.095
USD
+0.09%

AA
Alcoa Corp
32.730
USD
+0.31%

CACI
CACI International Inc
509.750
USD
+1.59%

PEN
Penumbra Inc
254.040
USD
+0.15%

SSB
SouthState Bank Corp
101.570
USD
+1.53%

NICE
Nice Ltd
149.010
USD
+0.68%

DOCS
Doximity Inc
72.725
USD
+0.31%

BLD
TopBuild Corp
402.930
USD
+0.06%

KNSL
Kinsale Capital Group Inc
426.325
USD
+0.64%
FAQ

Is Qiagen NV (QGEN) currently overvalued or undervalued?
Qiagen NV (QGEN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 19.02 is considered Undervalued compared with the five-year average of 21.52. The fair price of Qiagen NV (QGEN) is between 54.97 to 64.15 according to relative valuation methord. Compared to the current price of 45.87 USD , Qiagen NV is Undervalued By 16.57% .

What is Qiagen NV (QGEN) fair value?

How does QGEN's valuation metrics compare to the industry average?

What is the current P/B ratio for Qiagen NV (QGEN) as of Sep 23 2025?

What is the current FCF Yield for Qiagen NV (QGEN) as of Sep 23 2025?

What is the current Forward P/E ratio for Qiagen NV (QGEN) as of Sep 23 2025?
